Pfizer’s vaccine offers full protection for adolescents aged between 12 and 15.
The results of the phase three clinical trial have just shown that Pfizer is 100 percent effective against COVID-19 for adolescents between 12 and 15. Even though the study hasn’t been peer-reviewed just yet, it included 2,260 adolescents and the results bring a lot of good news.
A statement released on March 31 confirmed that the study results have demonstrated a
100 percent efficacy against COVID-19 and robust antibody responses in adolescents aged between 12 and 15. There were also no signs of serious side effects after vaccination.
As Pfizer CEO Albert Bourla said in the press release, “We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15.”
Read also: COVID-19 Complications That Might Stay With You Forever.
